MGRX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of positive earnings.
- Low Price-to-Book (0.35)
- Excessive Price-to-Sales (14.63) for a shrinking company
- No earnings to support a P/E valuation
Negative growth trends across all timeframes.
- Revenue Growth (YoY) -10.30%
- Q/Q Revenue Growth -10.34%
Consistent and severe destruction of shareholder equity.
- 5Y Change: -99.3%
- 1Y Change: -78.4%
- 6M Change: -84.5%
F-Score indicates the company is in the weakest possible health category.
- Low Debt/Equity (0.02)
- Piotroski F-Score 1/9
- ROE -141.66%
- ROA -69.91%
Company is not in a position to return capital.
- No dividend history
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MGRX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MGRX
Mangoceuticals, Inc.
Primary
|
-99.3% | -97.5% | -78.4% | -84.5% | +2.4% | +2.4% |
|
ITOC
iTonic Holdings Ltd.
Peer
|
-92.6% | -92.6% | -90.8% | -60.0% | -17.4% | -8.2% |
|
LUCY
Lucyd, Inc
Peer
|
-99.1% | -98.6% | -48.1% | -41.2% | -1.8% | +1.9% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MGRX
Mangoceuticals, Inc.
|
BEARISH | $6.67M | - | -141.7% | -% | $0.39 | |
|
ITOC
iTonic Holdings Ltd.
|
BEARISH | $6.92M | - | -71.2% | -% | $0.28 | Compare |
|
LUCY
Lucyd, Inc
|
BEARISH | $6.93M | - | -83.6% | -285.2% | $1.1 | Compare |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | JOHNSTON EUGENE M | Chief Financial Officer | Sale | 3,333 | $3,884 |
| 2025-12-09 | JOHNSTON EUGENE M | Chief Financial Officer | Sale | 5,000 | $5,975 |
| 2025-12-05 | JOHNSTON EUGENE M | Chief Financial Officer | Sale | 10,000 | $11,280 |
| 2025-11-19 | HAMILTON ALEX P | Director | Sale | 125,000 | $152,875 |
Past News Coverage
Recent headlines mentioning MGRX from our newsroom.